Announcements Trials
Browse Landscape

Phase

Phase 2 79Phase 1 18Phase 1/2 13Phase 3 6Phase NA 5Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplastic Cells, Circulating 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × osimertinib × Clear all
NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Thoracic

Lung Neoplasms

NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Second Affiliated Hospital of Nanchang University

Phase EARLY_PHASE1 Not yet recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡